How the Use of Alternative Medicine Hurts Survival Rates in Patients with Cancer
September 12th 2019Two doctors discuss their research on how use of alternative over traditional medicine affects survival rates in patients with cancer and how oncologists can approach the age of medical misinformation.
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
August 23rd 2019A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
Should Surveillance Schedules Apply to HPV-Associated Oropharyngeal Squamous Cell Carcinomas?
August 16th 2019A new study looked at what methods were used to detect recurrences of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma to see if surveillance guidelines recommended by the National Comprehensive Cancer Center were effective.
Are Conservative Management Approaches to Low-Risk Prostate Cancer Catching On?
August 9th 2019Researchers looked at data from the Surveillance, Epidemiology, and End Results database to see if there has been any increase in the use of active surveillance or watchful waiting when it comes to low-risk prostate cancer.